Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Change in Account Payables (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Change in Account Payables for 4 consecutive years, with -$443000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 12.1% to -$443000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$352000.0, a 82.72% increase, with the full-year FY2025 number at -$352000.0, up 82.72% from a year prior.
  • Change in Account Payables was -$443000.0 for Q4 2025 at Spruce Biosciences, down from $579000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q3 2023 to a low of -$2.5 million in Q2 2023.
  • A 4-year average of -$117500.0 and a median of -$131500.0 in 2023 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 217.97% in 2023; the steepest drop was 844.94% in 2023.
  • Spruce Biosciences' Change in Account Payables stood at -$755000.0 in 2022, then soared by 123.84% to $180000.0 in 2023, then tumbled by 380.0% to -$504000.0 in 2024, then grew by 12.1% to -$443000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Change in Account Payables are -$443000.0 (Q4 2025), $579000.0 (Q3 2025), and -$1.1 million (Q2 2025).